RedHawk Holdings Corp (fka SNDD)

[AlwaysRed]

You know Dan, I understand the anger. I mean you were a part of the team. Heck you may have even found the darn thing:

https://investingnews.com/daily/life-science-investing/medical-device-investing/redhawk-acquire-needle-disintegratortm/

But the fact remains:

"The Company also said that concurrent with the closing of the purchase of the Disintegrator(TM), Beechwood Properties, LLC (“Beechwood”) will inject up to $1 million into RedHawk for working capital purposes. Beechwood currently owns beneficially, 37.9% of RedHawk’s outstanding common stock. Mr. G. Darcy Klug, the Company’s Chief Financial Officer and Secretary, owns and controls Beechwood."

It has to sting.

And now look:

https://nomoresharps.com/

But sitting on your hands for years:

RedHawk Holdings Corp. (PINKSHEETS: IDNG) (“RedHawk” or the “Company”) announced today that its wholly-owned medical device subsidiary, RedHawk Medical Products & Services, LLC, has signed a non-binding Letter of Intent (“LOI”) to acquire all of the tangible and intangible property rights for the Disintegrator(TM) Insulin Needle Destruction Unit (“Disintegrator(TM)”), the only needle destruction device approved by the United States Food and Drug Administration (“FDA”). Closing is expected to be completed by December 31, 2015.

I mean you were excited about this:

"Announcing the acquisition of the Disintegrator(TM), Daniel J. Schreiber, RedHawk’s Chief Executive Officer, said “The healthcare industry generates hundreds of millions of tons of hazardous waste each year with used needles, some of which find their way into landfills worldwide. The Disintegrator(TM) can save the healthcare industry many millions of dollars annually with this environmentally friendly method for disposing used needles, a hazardous waste product, while establishing a safer workplace for millions of healthcare workers.”
Schreiber continued, “Needle disposal and needlestick concerns are not isolated to the United Kingdom. OSHA estimates 5.6 million healthcare industry workers in the United States are at risk of occupational exposure to bloodborne pathogens via needlestick injuries. Each year 385,000 needlestick injuries and other sharps-related injuries are sustained by U.S. hospital based healthcare personnel. This equates to an average of around 1,000 sharps injuries per day in U.S. hospitals. Including other non-acute healthcare facilities, it is estimated that 600,000 healthcare personnel incur a needlestick injury each year in the U.S. 40% of injuries occur after use and before disposal of sharp devices, 41% of injuries occur during the use of sharp devices on patients, and 15% of injuries occur during or after disposal. Virtually all healthcare personnel worldwide are at risk of harm from occupational exposures such as needlestick injuries. While nurses sustain approximately half of all needlestick injuries, physicians, housekeeping and maintenance staff, technicians and administrators are also harmed. According to the American Hospital Association, one case of serious infection by bloodborne pathogens can soon add up to $1 million or more in expenditures for testing, follow-up, and disability payments. Costs that are harder to quantify include the emotional cost associated with fear and anxiety from worrying about the possible consequences of an exposure, direct and indirect costs associated with drug toxicities and lost time from work.”

You knew the potential!

So off we go with a new CEO:

"Current market conditions have created business opportunities for us to capitalize upon while facing unique marketplace challenges. RedHawk Medical Products is certainly working to do its part to help meet difficult marketplace challenges and provide solutions to our community of customers," says Philip C. Spizale ("Spizale"), RedHawk's newly appointed Chief Executive Officer "Although we want to capitalize on each opportunity expeditiously, we won't sacrifice quality for speed. Our preliminary results for the three month period ended June 30, 2020 are projected to be at record levels, with our revenues for such period estimated to increase more than 500% over the preceding three month period ended March 31, 2020. Normalized quarterly cash flow from operations are also preliminarily estimated at record levels for this same three month period. We believe these revenue levels are continuing into the current three month period."

So Dan, how do you like them apples?: